These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 19010906

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.
    Hu Y, Wang L, Wang L, Wu X, Wu X, Gu Y, Shu Y, Sun Y, Shen Y, Xu Q.
    Toxicol Appl Pharmacol; 2015 Feb 15; 283(1):1-8. PubMed ID: 25576094
    [Abstract] [Full Text] [Related]

  • 24. Targeting endoplasmic reticulum signaling pathways in cancer.
    Martinon F.
    Acta Oncol; 2012 Sep 15; 51(7):822-30. PubMed ID: 22686473
    [Abstract] [Full Text] [Related]

  • 25. Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.
    Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, Ambinder RF.
    Blood; 2011 Jun 09; 117(23):6297-303. PubMed ID: 21447826
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.
    Cheng Y, Ren X, Zhang Y, Shan Y, Huber-Keener KJ, Zhang L, Kimball SR, Harvey H, Jefferson LS, Yang JM.
    Autophagy; 2013 Feb 01; 9(2):208-19. PubMed ID: 23182879
    [Abstract] [Full Text] [Related]

  • 28. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
    Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, Inazu M, Tomoda A, Miyazawa K.
    Int J Oncol; 2013 May 01; 42(5):1541-50. PubMed ID: 23546223
    [Abstract] [Full Text] [Related]

  • 29. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
    Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.
    Clin Cancer Res; 2011 Aug 01; 17(15):5101-12. PubMed ID: 21712452
    [Abstract] [Full Text] [Related]

  • 30. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
    Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlötzer-Schrehardt U, Voll RE.
    Neoplasia; 2010 Jul 01; 12(7):550-61. PubMed ID: 20651984
    [Abstract] [Full Text] [Related]

  • 31. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
    Selimovic D, Porzig BB, El-Khattouti A, Badura HE, Ahmad M, Ghanjati F, Santourlidis S, Haikel Y, Hassan M.
    Cell Signal; 2013 Jan 01; 25(1):308-18. PubMed ID: 23079083
    [Abstract] [Full Text] [Related]

  • 32. The unfolded protein response selectively targets active smoothened mutants.
    Marada S, Stewart DP, Bodeen WJ, Han YG, Ogden SK.
    Mol Cell Biol; 2013 Jun 01; 33(12):2375-87. PubMed ID: 23572559
    [Abstract] [Full Text] [Related]

  • 33. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
    Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT.
    Cancer Res; 2005 May 01; 65(9):3828-36. PubMed ID: 15867381
    [Abstract] [Full Text] [Related]

  • 34. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B.
    Oncogene; 2005 Jul 21; 24(31):4993-9. PubMed ID: 15824729
    [Abstract] [Full Text] [Related]

  • 35. Fold up or perish: unfolded protein response and chemotherapy.
    Strasser A, Puthalakath H.
    Cell Death Differ; 2008 Feb 21; 15(2):223-5. PubMed ID: 18049478
    [No Abstract] [Full Text] [Related]

  • 36. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.
    Mol Cancer Ther; 2006 Sep 21; 5(9):2378-87. PubMed ID: 16985072
    [Abstract] [Full Text] [Related]

  • 37. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R.
    Leukemia; 2010 Aug 21; 24(8):1506-12. PubMed ID: 20555361
    [Abstract] [Full Text] [Related]

  • 38. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
    Wada N, Kawano Y, Fujiwara S, Kikukawa Y, Okuno Y, Tasaki M, Ueda M, Ando Y, Yoshinaga K, Ri M, Iida S, Nakashima T, Shiotsu Y, Mitsuya H, Hata H.
    Int J Oncol; 2015 Mar 01; 46(3):963-72. PubMed ID: 25530098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.